• support@madhedgefundtrader.com
  • Member Login
Mad Hedge Fund Trader
  • Home
  • About
  • Store
  • Luncheons
  • Testimonials
  • Contact Us
  • Click to open the search input field Click to open the search input field Search
  • Menu Menu
Mad Hedge Fund Trader

The Tailwind Behind Beyond Meat

Tech Letter

Over 20,000 meat processing plant workers have contracted Covid-19 resulting in numerous deaths. I will explain why this has been a massive contributor to Beyond Meat’s (BYND) recent overperformance.

The Plant-Based Foods Association reported sales increasing over 90% in the middle of March 2020 from the year prior as animal-based meat shortages pervaded meat supply lines across the U.S.

Beyond Meat is one of the few publicly traded food tech companies out there and have been the recipient of several tailwinds all powering the company’s revenue at one time.

The pandemic has underscored the trend of consumers eating plant-based alternative options as a viable alternative.  

It has been one of those trends that have gone viral as consumers simply avoid meat because of a surge in prices caused by a sudden shortage.

The 90% growth of plant-based meat sales in mid-March was followed up by 27% growth in April.

The post-March follow-through leads me to believe that more than a few consumers were satisfied with the products and became repeat purchasers.

Since health has been a do-or-die proposition starting in March, there has been a continued evolvement in consumer purchasing toward natural and organic products that enhance health and immunity.

Not only are plant-based meats getting rewarded, but other categories of health foods have seen explosive growth.

Retail sales of plant-based meat products were higher by nearly 150% during peak panic buying in March and stayed above 50% through late April.

Refrigerated plant-based meat was the hottest-selling product registering a blistering increase in sales of 241% year-over-year during the peak panic buying period.

Plant-based foods have gone from the periphery of the food scene to the vanguard of sustainability and nutrition.

The coronavirus has also shined a light on how well companies treat their workers or the maltreatment of workers.

Meatpacking workers were holed up in tight areas causing a rapid outbreak of the virus which was thoroughly reported in the media and left a bad taste in consumers' mouth.

By the beginning of June, a survey revealed that 52% of respondents believe the food industry should focus more on meat-free foods to help reduce shortages.

The same survey of 1000 people also found that half of respondents don’t agree with the meat industry’s level of care about the health of its workers, and 65% don’t think it cares about the treatment of livestock.

The optics not only looked bad for the workers, but also for the product as the bottleneck in processing also led to the largest pig culling effort the U.S. has ever seen as hundreds of thousands of animals were backed up on farms.

This happened all while 40 million workers lost their jobs and bread lines formed as long as the eye could see in many of the big U.S. cities.

The animal-based meat industry has most likely had its worst-ever first half year to any financial year on record.

Fortunately, Beyond Meat has avoided the fate of the meat industry and is running with the momentum by announcing a partnership with food distributor Sinodis to further deliver products in China.

Sinodis, a subsidiary of French group Savencia, is a distributor of imported food products to more than 4500 wholesalers, restaurant chains, and hotels in China.

The deal fortifies Beyond Meat’s presence in China while supplementing new income streams.

Back in April, Beyond Meat also announced a bevy of new China openings with Starbucks (SBUX) and followed that up with deals with Kentucky Fried Chicken (KFC) and Pizza Hut.

The efforts to widen its customer reach has not gone unnoticed with the stock tripling from virus lows this year.

Ultimately, the adoption of U.S. mainstream customers in the wealthier suburbs will be critical to long-term success.

The company plans to broaden its product line into other forms of substitute meat, like poultry, to grow its top-line revenue.

The stock has more room to run and investors should wait for a dip to put new money to work.

Price action is volatile, meaning investors should buy and hold shares and not try to game the stock short-term.

beyond meat

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2020-06-10 09:32:212020-06-10 19:55:05The Tailwind Behind Beyond Meat
Mad Hedge Fund Trader

June 10, 2020 - Quote of the Day

Tech Letter

“Some say Google is God. Others say Google is Satan. But if they think Google is too powerful, remember that with search engines, unlike other companies, all it takes is a single click to go to another search engine.” – Said Google Co-Founder Sergey Brin

https://www.madhedgefundtrader.com/wp-content/uploads/2020/06/sergey-brin.png 173 145 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2020-06-10 09:30:202020-06-10 09:49:06June 10, 2020 - Quote of the Day
Mad Hedge Fund Trader

June 10, 2020 - MDT Pro Tips

MDT Alert

While the Diary of a Mad Hedge Fund Trader focuses on investment over a one week to a six-month time frame, Mad Day Trader, provided by Bill Davis, will exploit money-making opportunities over a brief ten minute to three-day window. It is ideally suited for day traders, but can also be used by long-term investors to improve market timing for entry and exit points. Read more

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2020-06-10 09:18:312020-06-10 09:18:31June 10, 2020 - MDT Pro Tips
Mad Hedge Fund Trader

June 10, 2020

Diary, Newsletter, Summary

Global Market Comments
June 10, 2020
Fiat Lux

Featured Trade:

(THE MAD HEDGE JUNE 4 TRADERS & INVESTORS SUMMIT RECORDING IS UP),
(HOW TO HANDLE THE FRIDAY, JUNE 19 OPTIONS EXPIRATION),
(TLT), (TBT)

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2020-06-10 08:06:282020-06-10 08:38:01June 10, 2020
Mad Hedge Fund Trader

How to Handle the Friday June 19 Options Expiration

Diary, Free Research, Newsletter

Followers of the Mad Hedge Fund Trader alert service have the good fortune to own a deep in-the-money options positions that expire on Friday, June 19, and I just want to explain to the newbies how to best maximize their profits.

This involves the:

the iShares Barclays 20+ Year Treasury Bond Fund (TLT) June 2020 $175-$180 in-the-money vertical Bear Put spread

the S&P 500 (SPY) June 2020 $235-$245 in-the-money vertical BULL CALL spread


Provided that we don’t have another 3,000-point move down in the market by next week, these positions should expire at their maximum profit points.

So far, so good.

I’ll do the math for you on our oldest iShares Barclays 20+ Year Treasury Bond Fund (TLT) position. Your profit can be calculated as follows:

Profit: $5.00 expiration value - $4.10 cost = $0.90 net profit

(24 contracts X 100 contracts per option X $0.90 profit per options)

= $2,160 or 21.95% in 34 trading days.

Many of you have already emailed me asking what to do with these winning positions.

The answer is very simple. You take your left hand, grab your right wrist, pull it behind your neck, and pat yourself on the back for a job well done.

You don’t have to do anything.

Your broker (are they still called that?) will automatically use your long position to cover your short position, canceling out the total holdings.

The entire profit will be credited to your account on Monday morning June  22 and the margin freed up.

Some firms charge you a modest $10 or $15 fee for performing this service.

If you don’t see the cash show up in your account on Monday, get on the blower immediately and find it.

Although the expiration process is now supposed to be fully automated, occasionally machines do make mistakes. Better to sort out any confusion before losses ensue.

If you want to wimp out and close the position before the expiration, it may be expensive to do so. You can probably unload them pennies below their maximum expiration value.

Keep in mind that the liquidity in the options market understandably disappears, and the spreads substantially widen, when a security has only hours, or minutes until expiration on Friday. So, if you plan to exit, do so well before the final expiration at the Friday market close.

This is known in the trade as the “expiration risk.”

One way or the other, I’m sure you’ll do OK, as long as I am looking over your shoulder, as I will be, always. Think of me as your trading guardian angel.

I am going to hang back and wait for good entry points before jumping back in. It’s all about keeping that “Buy low, sell high” thing going.

I’m looking to cherry-pick my new positions going into the next quarter-end.

Take your winnings and go out and buy yourself a well-earned dinner. Just make sure it’s take-out. I want you to stick around.

Well done, and on to the next trade.

 

https://www.madhedgefundtrader.com/wp-content/uploads/2019/09/john-and-girls.png 322 345 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2020-06-10 08:02:082020-09-28 12:12:21How to Handle the Friday June 19 Options Expiration
Mad Hedge Fund Trader

June 9, 2020 - MDT Alert (MFA)

MDT Alert

I had recommended MFA back on March 20th based on two scenarios.

The first was that the stock carried a decent call option premium. And the second reason was because at the time, they were paying a hefty dividend.

With the turmoil in the mortgage market created by the Covid-19 pandemic, MFA has been forced to eliminate its dividend and deleverage.

Therefore, I am going to recommend you sell call options at every opportunity you get.

And this is one of those opportunities.

Here is the suggestion.

Sell to Open (1) June 19th - $4 call for every 100 shares you own. The June $4 calls can be sold for $0.65.

I know these calls are slightly in the money, but you should have
collected $0.40 in call premium on this position already.

This is more of a hedge at this point.

This alert applies only if you own shares in MFA.

If you followed the original alert, you would own 1,000 shares of MFA. Therefore you would be selling 10 calls.

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2020-06-09 10:26:582020-06-09 10:26:58June 9, 2020 - MDT Alert (MFA)
Mad Hedge Fund Trader

June 9, 2020

Biotech Letter

Mad Hedge Biotech & Healthcare Letter
June 9, 2020
Fiat Lux

Featured Trade:

(HERE ARE FIVE VACCINE FRONTRUNNERS TO BUY NOW)
(MRNA), (AZN), (JNJ), (MRK), (PFE), (GSK), (SNY), (NVAX), (INO), (MYL)

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2020-06-09 10:02:472020-06-09 10:42:24June 9, 2020
Mad Hedge Fund Trader

Here Are Five Vaccine Frontrunners to Buy Now

Biotech Letter

Among hundreds of companies working on a coronavirus disease (COVID-19) vaccine, the US Government has picked five companies as the most likely candidates to develop the much-needed immunization shot soon.

This is a part of a process that usually takes years and even decades to complete. The goal is to have a COVID-19 vaccine available for Americans by January 2021.

The decision to winnow the field even before final results are out is the administration’s way of focusing its energy and resources on the most promising vaccine candidates, thereby coming up with a solution faster.

Four of the five companies are based in the United States and one is from the United Kingdom.

The list includes Massachusetts-based biotechnology firm Moderna (MRNA), which has a market capitalization of $22.63 billion.

It also features biotechnology and healthcare giants Johnson & Johnson (JNJ), with its $388.08 billion market cap; Merck & Co. (MRK), which has $207.63 billion in market cap, and Pfizer (PFE), with a market cap of $199.92 billion.

Cambridge-based pharmaceutical and biopharmaceutical company AstraZeneca rounds up the list.

Both Moderna and AstraZeneca are already in Phase 2 trials, which means the companies are testing their candidates on human subjects.

Looking at their timeline, the two would most likely move forward to Phase 3, which involves large-scale human trials, in July.

The Phase 3 trials will require roughly 30,000 participants for each vaccine candidate. If all five vaccine candidates reach Phase 3, then that means 150,000 people will be asked to participate as test subjects.

What we do know so far is that the agreements involve commitments from the biotechnology companies regarding intellectual property, the number of doses expected, and the estimated price limits.

Here’s a brief background of the top five companies under Trump’s COVID-19 vaccine radar today.

Moderna (MRNA)

Moderna’s vaccine, called mRNA1273, is undergoing Phase 2 trials. When news broke about Moderna’s progress with the COVID-19 vaccine, shares of the company exploded by more than 200% year-to-date.

For its Phase 2 trial, Moderna seeks to enroll 600 healthy individuals to test mRNA-1273 administered 28 days apart.

Throughout the COVID-19 crisis, Moderna has been a clear favorite of NIH’s Dr. Anthony Fauci.

He called the vaccine “quite promising” and described the results of the Phase 1 study to be “better than we thought.” What we know about the vaccine is that it can “neutralize” the virus in patients.

In terms of its release, Moderna is projected to deploy mRNA-1273 by the end of 2020.

AstraZeneca (AZN)

AstraZeneca joined forces with Oxford University to develop AZD1222, which is now undergoing clinical trials in many sites in the UK.

Although the two have yet to complete its trials, AstraZeneca already agreed to supply 400 million vaccine doses to both the US and the UK in May.

Earlier this month, the company again completed a $750 million agreement with the Coalition for Epidemic Preparedness Innovations (CEPI), Gavi the Vaccine Alliance, and the Serum Institute of India (SII) to provide 1 billion vaccine doses to low and middle-income patients.

Johnson & Johnson (JNJ)

Johnson & Johnson aims to begin its Phase 1 clinical trial by September, with the ultimate goal to supply over 1 billion doses of COVID-19 vaccine across the globe.

Although Moderna and AstraZeneca are ahead in terms of vaccine development, JNJ has been impressing investors with its efforts outside COVID-19.

In the first quarter of 2020, the healthcare giant showed off a 3.3% year-over-year jump in its sales and a 54.6% increase in its net earnings.

The revenue of its pharmaceutical division rose by 8.7% while its health division saw a 9.2% increase.

Dubbed as the “Dividend King” in the industry, JNJ stayed true to its title as it continues its 58-year streak of raising its quarterly dividend.

Reports show that the company raised its quarterly dividend by 6.3% to reach $1.01 per share, reaping a solid yield of 2.73%.

Regardless of its performance in the vaccine race, JNJ has proven its resilience not only in the COVID-19 crisis but also in past crises like the dot-com bubble and the collapse of the housing market.

Merck (MRK)

Merck’s strategy is to build on the technology of its successful Ebola vaccine and establish partnerships with non-profit research groups.

Like JNJ, Merck is also a stable dividend stock that investors can buy and hold for years. In the past 10 years, this biotechnology leader has posted a profit, even managing to hit double-digits the majority of the time.

This is a trend Merck once again showcased in the first quarter of 2020.

In its latest report, the company showed off $3.2 billion in profit in sales worth $12.1 billion — demonstrating a decent profit margin of 27%.

Sales increased by 11% year over year, with cancer drug Keytruda heading the charge with its 45% revenue growth from the same period in 2019.

Pfizer (PFE)

Pfizer has been collaborating with German drugmaker BioNTech (BNTX) to develop BNT162.

The pharma giant is expected to have the vaccine candidate ready by October this year and be able to produce “hundreds of millions” of COVID-19 doses by 2021.

Although Pfizer and BioNTech joined the race later than Moderna, the big healthcare company’s edge is that it’s actually working on four vaccines simultaneously.

Simply put, this strategy offers them more than a single change of winning.

Along with the other three big biotechnology companies, Pfizer is a safe bet for those looking to invest in cutting-edge vaccine efforts but don’t feel comfortable risking it with a clinical-stage firm.

Like JNJ and Merck, Pfizer’s vaccine work sounds promising, but even if its COVID-19 program falters, the healthcare giant can still make a strong case as an excellent investment.

In its first-quarter report for 2020, Pfizer’s biopharma arm indicated an 11% jump, thanks to top performers like blood clot treatment Eliquis whose sales climbed by 29% to reach $1.3 billion.

Breast cancer medication Ibrance also contributed $1.2 billion, showing off a 10% year-over-year growth while Xtandi sales increased by 25% year over year to record $209 million.

Aside from these, Pfizer is hard at work in spinning off its Upjohn unit to combine with Mylan (MYL). This deal will guarantee Pfizer shareholders with 57% share of the new company called Viatris.

Just a few weeks ago, Trump compared Operation Warp Speed to the Manhattan Project, which was a government-initiated program that led to the development of nuclear weapons in World War II.

However, critics say that the “Skunk Works” initiative in California is a more fitting comparison for this COVID-19 effort. That is, the government could simply be wasting its resources on candidates that might never be able to leave the design stage.

Regardless of where you stand on Trump’s Operation Warp Speed, the fact remains that countless biotechnology and healthcare companies — big and small — are working on a COVID-19 vaccine.

Outside the five companies chosen by the Trump administration, the list of strong contenders includes GlaxoSmithKline (GSK) and Sanofi (SNY).

Even smaller biotechnology companies like Inovio (INO) and Novavax (NVAX) are going all out on this.

Of course, it would also be foolish to completely disregard CanSino Biologics, which has been giving Moderna a run for its money since Day 1.

 Despite not making the cut, these biotechnology and healthcare companies are still in hot pursuit and it’s still very much a neck-to-neck race.

vaccine covid-19

 

vaccine covid-19

 

vaccine covid-19

 

 

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2020-06-09 10:00:452020-06-10 20:19:39Here Are Five Vaccine Frontrunners to Buy Now
Mad Hedge Fund Trader

June 9, 2020 - MDT Pro Tips

MDT Alert

While the Diary of a Mad Hedge Fund Trader focuses on investment over a one week to a six-month time frame, Mad Day Trader, provided by Bill Davis, will exploit money-making opportunities over a brief ten minute to three-day window. It is ideally suited for day traders, but can also be used by long-term investors to improve market timing for entry and exit points. Read more

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2020-06-09 09:24:432020-06-09 09:24:43June 9, 2020 - MDT Pro Tips
Mad Hedge Fund Trader

June 9, 2020

Diary, Newsletter, Summary

Global Market Comments
June 9, 2020
Fiat Lux

Featured Trade:

(HOW TO EXECUTE A VERTICAL BULL CALL SPREAD)
(AAPL)
(THE NEW CODER BOOM)

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2020-06-09 09:06:472020-06-09 08:25:39June 9, 2020
Page 12 of 17«‹1011121314›»

tastytrade, Inc. (“tastytrade”) has entered into a Marketing Agreement with Mad Hedge Fund Trader (“Marketing Agent”) whereby tastytrade pays compensation to Marketing Agent to recommend tastytrade’s brokerage services. The existence of this Marketing Agreement should not be deemed as an endorsement or recommendation of Marketing Agent by tastytrade and/or any of its affiliated companies. Neither tastytrade nor any of its affiliated companies is responsible for the privacy practices of Marketing Agent or this website. tastytrade does not warrant the accuracy or content of the products or services offered by Marketing Agent or this website. Marketing Agent is independent and is not an affiliate of tastytrade. 

Legal Disclaimer

There is a very high degree of risk involved in trading. Past results are not indicative of future returns. MadHedgeFundTrader.com and all individuals affiliated with this site assume no responsibilities for your trading and investment results. The indicators, strategies, columns, articles and all other features are for educational purposes only and should not be construed as investment advice. Information for futures trading observations are obtained from sources believed to be reliable, but we do not warrant its completeness or accuracy, or warrant any results from the use of the information. Your use of the trading observations is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness of the information. You must assess the risk of any trade with your broker and make your own independent decisions regarding any securities mentioned herein. Affiliates of MadHedgeFundTrader.com may have a position or effect transactions in the securities described herein (or options thereon) and/or otherwise employ trading strategies that may be consistent or inconsistent with the provided strategies.

Copyright © 2025. Mad Hedge Fund Trader. All Rights Reserved. support@madhedgefundtrader.com
  • Privacy Policy
  • Disclaimer
  • FAQ
Scroll to top